JP2024527020A5 - - Google Patents

Info

Publication number
JP2024527020A5
JP2024527020A5 JP2024504772A JP2024504772A JP2024527020A5 JP 2024527020 A5 JP2024527020 A5 JP 2024527020A5 JP 2024504772 A JP2024504772 A JP 2024504772A JP 2024504772 A JP2024504772 A JP 2024504772A JP 2024527020 A5 JP2024527020 A5 JP 2024527020A5
Authority
JP
Japan
Prior art keywords
terminus
antigen
domain
region
peptide linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/071060 external-priority patent/WO2023006809A1/en
Publication of JP2024527020A publication Critical patent/JP2024527020A/ja
Publication of JP2024527020A5 publication Critical patent/JP2024527020A5/ja
Pending legal-status Critical Current

Links

JP2024504772A 2021-07-27 2022-07-27 抗原結合分子の組合せ Pending JP2024527020A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21187924 2021-07-27
EP21187924.2 2021-07-27
PCT/EP2022/071060 WO2023006809A1 (en) 2021-07-27 2022-07-27 Combinations of antigen binding molecules

Publications (2)

Publication Number Publication Date
JP2024527020A JP2024527020A (ja) 2024-07-19
JP2024527020A5 true JP2024527020A5 (cg-RX-API-DMAC7.html) 2025-09-02

Family

ID=77103832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504772A Pending JP2024527020A (ja) 2021-07-27 2022-07-27 抗原結合分子の組合せ

Country Status (7)

Country Link
US (1) US20250101103A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377347A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527020A (cg-RX-API-DMAC7.html)
CN (1) CN117715939A (cg-RX-API-DMAC7.html)
AU (1) AU2022318255A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227537A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023006809A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217894A1 (en) * 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025237931A1 (en) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
MX359411B (es) 2012-01-13 2018-09-27 Univ Wuerzburg J Maximilians Complementación funcional bipartita inducida por antígenos, dual.
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
JP6696982B2 (ja) * 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
IL274071B2 (en) * 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
CN121591910A (zh) * 2017-11-21 2026-03-03 诺华股份有限公司 针对肿瘤相关抗原的三特异性结合分子及其用途
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
WO2019199916A1 (en) * 2018-04-13 2019-10-17 Eli Lilly And Company Fab-based trispecific antibodies
KR102956533B1 (ko) 2018-07-02 2026-04-24 더 제너럴 하스피탈 코포레이션 항체 종양-표적화 조립 복합체
WO2020023553A1 (en) * 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CA3121699A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
EP3959237A1 (en) 2019-04-25 2022-03-02 F. Hoffmann-La Roche AG Therapeutic multispecific polypeptides activated by polypeptide chain exchange
JP7812230B2 (ja) 2019-04-25 2026-02-09 エフ. ホフマン-ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
AU2020263910A1 (en) 2019-04-25 2021-10-21 F. Hoffmann-La Roche Ag Activatable therapeutic multispecific polypeptides with extended half-life
CA3138854A1 (en) 2019-05-02 2020-11-05 The General Hospital Corporation Teac and attac immunooncology compositions and methods
MX2022001942A (es) * 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
JP7851303B2 (ja) 2020-09-24 2026-04-24 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒトcd3イプシロンに結合する新規なヒト抗体

Similar Documents

Publication Publication Date Title
JP7457764B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
JP2023548443A5 (cg-RX-API-DMAC7.html)
Deyev et al. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design
JP2020517287A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
US20040220388A1 (en) Novel heterodimeric fusion proteins
JP2020186248A5 (cg-RX-API-DMAC7.html)
JP2021525530A5 (cg-RX-API-DMAC7.html)
JP2023509212A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
ES2967739T3 (es) Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
JP2021159081A5 (cg-RX-API-DMAC7.html)
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2016536322A5 (cg-RX-API-DMAC7.html)
JP2014158485A5 (cg-RX-API-DMAC7.html)
SI2573121T1 (en) Antibodies that bind IL-4 and/or IL-13 and their uses
JP2022532370A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2024113040A5 (cg-RX-API-DMAC7.html)
JP2019535315A5 (cg-RX-API-DMAC7.html)
JP2022504826A5 (cg-RX-API-DMAC7.html)
JP2023544211A5 (cg-RX-API-DMAC7.html)
JP2023552462A5 (cg-RX-API-DMAC7.html)
JP2019505565A5 (cg-RX-API-DMAC7.html)